Table 1.
List of clinical trials with anti-cancer drugs targeting COX-2, IDO1, or TDO2 in various cancers. Taken from https://clinicaltrials.gov/, last accessed 31 August 2021.
| Target | Inhibitor | Strategy (Combination) | NCT Number | Phase | Type of Cancer | Status |
|---|---|---|---|---|---|---|
| IDO1 | 1-methyl-D-tryptophan | alone | NCT00739609 | 1 | breast cancer, lung cancer, melanoma, pancreatic cancer, solid tumors | terminated |
| IDO1 | GDC-0919 (navoximod) | alone | NCT02048709 | 1 | solid tumors | completed |
| FIXEDIDO1 | LY3381916 | LY3300054 (anti-PD-L1 checkpoint antibody) | NCT03343613 | 1 | non-small cell lung cancer, renal cell carcinoma, triple negative breast cancer | terminated |
| IDO1 | NLG802 | alone | NCT03164603 | advanced solid tumors | completed | |
| IDO1 | BMS-986205 | nivolumab + ipilimumab | NCT03459222 | 2 | advanced cancer | recruiting |
| IDO1 | BMS-986205 | alone | NCT03695250 | 1 | liver cancer | active, not recruiting |
| + nivolumab | 2 | |||||
| IDO1 | BMS-986205 | nivolumab + temozolomide + radiotherapy | NCT04047706 | 1 | glioblastoma | recruiting |
| IDO1 | epacadostat (INCB024360) | itacitinib (JAK inhibitor) + INCB050465 PI3K-delta inhibitor | NCT02559492 | 1 | solid tumors | terminated |
| IDO1 | epacadostat (INCB024360) | nivolumab + anti-GITR monoclonal antibody MK-4166 + ipilimumab | NCT03707457 | 1 | glioblastoma | terminated |
| IDO1 | epacadostat (INCB024360) | ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine | NCT01982487 | 1 | epithelial ovarian, fallopian tube, peritoneal cancer | withdrawn |
| alone | 2 | |||||
| IDO1 | epacadostat (INCB024360) | DEC-205/NY-ESO-1 fusion protein CDX-1401 + Poly ICLC | NCT02166905 | 2 | fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma | completed |
| IDO1 | epacadostat (INCB024360) | pembrolizumab | NCT03414229 | 2 | sarcoma | active, not recruiting |
| IDO1 | epacadostat (INCB024360) | pembrolizumab | NCT03432676 | 2 | advanced pancreatic cancer | withdrawn |
| IDO1 | epacadostat (INCB024360) | cyclophosphamide | NCT02785250 | 2 | ovarian cancer | active, not recruiting |
| IDO1 | epacadostat (INCB024360) | ipilimumab | NCT01604889 | 2 | metastatic melanoma | terminated |
| IDO1 | epacadostat (INCB024360) | azacitidine (DNA methyltransferase inhibitor) + pembrolizumab | NCT02959437 | 2 | metastatic cancer | terminated |
| INCB057643 + pembrolizumab | ||||||
| INCB059872 + pembrolizumab | ||||||
| IDO1 | epacadostat (INCB024360) | pembrolizumab + cisplatin + cetuximab + carboplatin + 5-fluorouracil | NCT03358472 | 3 | head and neck cancer | active, not recruiting |
| IDO1 | epacadostat (INCB024360) | pembrolizumab + sunitinib + pazopanib | NCT0360894 | 3 | renal cell carcinoma | active, not recruiting |
| IDO1 and TDO2 | DN1406131 | alone | NCT03641794 | 1 | advanced solid tumors | recruiting |
| IDO1 and TDO2 | HTI-1090 | alone | NCT03208959 | 1 | advanced solid tumors | completed |
| TDO2 and IDO1 | DN1406131 | alone | NCT03641794 | 1 | advanced solid tumors | unknown |
| COX2 | celecoxib 200 mg capsule | alone | NCT03896113 | 2 | endometrial carcinoma | recruiting |